GH secretagogue

GHRP-2

Controlled trials

Synthetic hexapeptide ghrelin receptor (GHS-R1a) agonist.

SubQIMIntermediateApproved outside the USmuscle growthrecovery and sleepappetite controlinjury repair

Also known as Pralmorelin · KP-102 · GHRP-2 acetate

At a glance

Dose summary

Typical dose200 mcg
Range100 mcg–300 mcg
FrequencyDaily
Half-life~1 h
ScheduleOnce daily
Cycle length12 weeks
RouteSubQ · IM
Experience levelIntermediate
Evidence gradeControlled trials
ApprovalApproved outside the US
Where the dose comes fromCommunity practice, not a trial

No regulator and no trial set these numbers. They describe what people actually do, recorded so you can see the range rather than guess at it — which is not the same thing as a recommendation.

Reconstitution

What to draw, at the usual vial

A 10 mg vial reconstituted with 2 mL of bacteriostatic water gives 5.00 mg/mL. A typical 200 mcg dose is 0.040 mL — pull the plunger to 4 units on a U-100 syringe.

Concentration5.00 mg/mL
Draw volume0.040 mL
U-100 units4 units
Doses per vial50

Same dose, other vial sizes

VialWaterConcentrationDrawUnitsDoses
10 mg2 mL5.00 mg/mL0.040 mL4 units50

The highlighted row is the one quoted above: the smallest listed vial that holds at least four typical doses. Change any of it — a different vial, more or less water, a different dose — on the reconstitution calculator, which draws the syringe to true U-100 graduations.

Mechanism & evidence

What it is, and what is known

Synthetic hexapeptide ghrelin receptor (GHS-R1a) agonist. Unusually for this corner of the market it has real human data: it has been studied as a growth hormone secretagogue in published dose-response work, and the same molecule is registered in Japan as pralmorelin for use as a single-dose diagnostic test of growth hormone deficiency. That diagnostic use is a one-off intravenous challenge, not a chronic subcutaneous protocol, so the human evidence supports the fact that it releases growth hormone rather than the community habit of dosing it daily for months.

It is not approved for physique or anti-ageing use anywhere. It is less selective than ipamorelin: expect measurable prolactin and cortisol elevation, which is the usual reason people switch away from it. The 100-300 mcg per dose range, often split into two or three doses a day, comes from practice rather than from a label.

The caveat

Registered in Japan as pralmorelin — a single-dose diagnostic challenge, not a chronic protocol. The human data supports that it releases GH, not that dosing it for months is wise.

Tolerability

Reported side effects

  • Raises prolactin and cortisol more than ipamorelin does — this is its main practical drawback, and it scales with dose, so pushing past roughly 300 mcg per injection buys little extra growth hormone while making the hormonal spillover worse
  • Hunger spike within about half an hour of dosing, which works against a cut
  • Water retention, morning puffiness, and numb or tingling hands
  • Head rush, flushing or brief light-headedness just after injection
  • Blunted response over months of uninterrupted daily use, so it is usually cycled
  • Injection site redness or itching

Hard stops

Do not use this if

  • Pregnancy, possible pregnancy, or breastfeeding
  • Active, suspected or recently treated malignancy
  • Under 18

These are flags, not a screening. They do not replace a conversation with a clinician who knows your history.

Handling

Storage

Sealed powder, refrigerated24 months
After reconstitution, refrigerated30 days

Keep it cold, keep it dark, and label the vial with the date you mixed it. Discard anything cloudy or past the window above.

Combinations

Commonly stacked with

Stacking multiplies the side-effect surface and makes it impossible to tell which compound did what. Add one thing at a time.

References

Sources

Educational information only, not medical advice. Talk to a licensed clinician before starting, changing, or stopping anything.